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ity,1 which is overexpressed in 30% to 40% of breast
carcinoma, ovarian carcinoma, and non–small cell
lung cancer (NSCLC).2 Recent studies have indicated
that p185 overexpression correlates with enhanced
cellular resistance to a variety of chemotherapeutic
agents, including cisplatin, etoposide, doxorubicin
A lthough still not fully defined, the molecular basisof chemoresistance in cancer appears to be a col-
lective result of many complex genetic factors, one of
which is overexpression of the oncogene erbB-2. This
oncogene encodes a 185-kd transmembrane receptor
glycoprotein (p185) with intrinsic tyrosine kinase activ-
Objective: Overexpression of the oncogene erbB-2 contributes to chemo-
resistance in various malignant tumors including lung cancer. The aim
of this study was to investigate whether depletion of the erbB-2 gene
product (p185) by 17-allylamino 17-demethoxygeldanamycin would
sensitize lung cancer cells to paclitaxel (Taxol) in vitro. Methods:
Paclitaxel cytotoxicity was evaluated in a panel of non–small cell lung
cancer cell lines that expressed varying levels of p185 by means in vitro
proliferation assays and 2 drug combination schedules. Cell cycle kinet-
ics and apoptosis after exposure to paclitaxel or paclitaxel plus 17-allyl-
amino 17-demethoxygeldanamycin were analyzed by flow cytometry.
Results: The 17-allylamino 17-demethoxygeldanamycin treatment effi-
ciently depleted p185 expression in lung cancer cells. Concurrent expo-
sure of these cells to paclitaxel and 17-allylamino 17-demethoxygel-
danamycin significantly enhanced paclitaxel-mediated cytotoxicity,
particularly in cells which overexpressed p185. There was a 1.3 to more
than 20-fold reduction of paclitaxel 50% inhibitory concentration values
in those cells that were responding positively to the drug combination.
Significant induction of apoptosis was observed after treatment of cells
with the combination of paclitaxel and 17-allylamino 17-demethoxygel-
danamycin. The combination cytotoxic effect was only additive in cells
expressing low levels of p185. In contrast, of lung cancer cells with expo-
sure to 17-allylamino 17-demethoxygeldanamycin before combined
paclitaxel and 17-allylamino 17-demethoxygeldanamycin exposure
actually rendered the cells refractory to paclitaxel cytotoxicity.
Conclusion: The compound 17-allylamino 17-demethoxygeldanamycin
sensitizes non–small cell lung cancer cells expressing high levels of p185
to paclitaxel-mediated growth arrest and apoptosis. These preclinical
data support the evaluation of the combination of paclitaxel and 17-
allylamino 17-demethoxygeldanamycin in the treatment of patients with
lung cancer whose tumors exhibit p185 overexpression. (J Thorac
Cardiovasc Surg 1999;118:908-15)
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(Adriamycin), and paclitaxel (Taxol).2-6 Overexpres-
sion of p185 correlates with poor response to treatment
and diminished survival among patients with breast,
ovarian, and lung carcinomas.7-9
The benzoquinone ansamycin antibiotic geldanamycin
and its less toxic synthetic derivative 17-allylamino 17-
demethoxygeldanamycin (17-AAGA) have recently
been selected for clinical development at the National
Cancer Institute because of their activity against cell
lines derived from a variety of human malignancies.10,11
These agents have been shown to inhibit p185 expres-
sion in breast and lung cancer cells at nanomolar con-
centrations.5,12 Geldanamycin and 17-AAGA bind to
GRP94 (a member of the heat shock protein (HSP) 90
family of stress proteins), displacing p185 and resulting
in rapid degradation of this oncoprotein.13,14
In this study we sought to evaluate whether 17-
AAGA–mediated depletion of p185 could enhance sen-
sitivity to paclitaxel in NSCLC cell lines. Our analysis
revealed that inhibition of p185 expression correlated
with enhanced sensitivity to paclitaxel in NSCLC cell
lines that constitutively express high levels of this
oncoprotein. The synergistic combination effect was
dependent on the sequence of drug exposure. More-
over, downward regulation of p185 expression by 17-
AAGA in p185-overexpressing cell lines augmented
paclitaxel-induced apoptosis.
Materials and methods
Cell lines and reagents. The NSCLC cell lines H460,
H1299, H358, and H322 were available in tissue culture
banks at the National Cancer Institute; the NSCLC cell lines
H661 and H522 were purchased from American Type Culture
Collection (Manassas, Va). Cells were maintained in Roswell
Park Memorial Institute media supplemented with glutamine
(2 mmol/L), streptomycin (100 m g/mL) and penicillin (100
U/mL), and 5% or 10% fetal calf serum (all purchased from
BioFluids, Rockville, Md). Normal human bronchial epithe-
lial cells were purchased from Clonetics (BioWhittaker, Inc—
A Cambrex Company, Walkersville, Md). The 17-AAGA,
obtained from the Drug Synthesis & Chemistry Branch,
Developmental Therapeutic Program, Division of Cancer
Treatment, National Cancer Institute, was dissolved in
dimethyl sulfoxide to yield a 100-m mol/L stock solution and
stored at –70°C. All experiments involving this compound
were performed under subdued light conditions. Paclitaxel
(Taxol USP) was purchased from Bristol-Myers Squibb
Company (New York, NY). MTT (4,5-dimethylthiazo-2-yl)-
2,5-diphenyl tetrazolium bromide) was purchased from
Sigma (St Louis, Mo). Cellular p185 levels were measured
with an enzyme-linked immunosorbent assay kit from
Oncogene Science Diagnostics (Cambridge, Mass).
In vitro cell proliferation and drug combination sched-
ules. Cells were seeded in flat-bottom 96-well microtiter
plates at densities predetermined for each cell line to avoid
confluence at the end of experiments. After an overnight
incubation, cells were treated either with paclitaxel alone or
with the combination of paclitaxel and 17-AAGA according
to the following schedules.
Schedule A. A 90-minute exposure to varying doses of
paclitaxel concurrently with 17-AAGA (20, 40, or 80
nmol/L) was followed by 2 washes with phosphate-buffered
saline solution to remove unbound drugs and then further
incubated for 96 hours in media containing appropriate con-
centrations of 17-AAGA.
Schedule B. A 24-hour 17-AAGA exposure was followed
by concurrent drug exposure identical to that in schedule A.
Both schedules. In both schedules 17-AAGA was continu-
ously present in the culture media with replenishment every
48 hours; this was essential because the effect of 17-AAGA
on p185 depletion has been shown to be short-lived and
reversible.15 At the end of the incubation period viable cells
were quantitated by MTT colorimetric assays as described by
the manufacturer. Paclitaxel dose-response curves of cells
treated with paclitaxel alone were plotted as fraction of viable
cells relative to cells grown in normal media versus paclitax-
el doses, whereas those of cells treated with the paclitaxel and
17-AAGA combination were plotted as fraction of viable
cells relative to cells grown in 17-AAGA–containing media
(to correct for the minor growth inhibitory effect of 17-
AAGA) versus paclitaxel doses. Paclitaxel 50% inhibitory
concentration (IC50) values for cells treated with paclitaxel
alone or paclitaxel in combination with 17-AAGA were
derived from the respective dose-response curves. A reduc-
tion of paclitaxel IC50 values in cells treated with the drug
combination indicated and increase by 17-AAGA in the cel-
lular responsiveness to paclitaxel’s cytotoxic effects.
Flow cytometric analysis of cell cycle kinetics and apop-
tosis. Cell cycle kinetics and programmed cell death in non-
synchronized cells grown in the presence or absence of drugs
were analyzed by propidium iodide staining16 and TUNEL
(terminal deoxynucleotidyltransferase–mediated dUTP nick
end labeling) method using the Apo-BRDU kit (Phoenix Flow
Systems, San Diego, Calif) respectively and the FACScan
apparatus (Becton Dickinson and Company, Franklin Lakes,
NJ).
Statistical analysis. Data are expressed as mean ± SD. The
Student t test and 1-way analysis of variance (with
Bonferroni test for pairwise comparisons) were used for sta-
tistical analysis with the Prism 2.0 software package from
GraphPad Software, Inc (San Diego, Calif).
Results
Constitutive p185 expression in NSCLC. In pre-
liminary studies p185 expression in NSCLC cells was
quantitated with enzyme-linked immunosorbent assay
techniques. This analysis indicated that H460 and
H1299 cells expressed relatively low levels of p185
(4.3 and 6.5 erbB-2 units/m g protein, respectively),
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which nevertheless were 2.5- to 3.5-fold higher than
the level of p185 expression in confluent normal
human bronchial epithelial cells. The other NSCLC
lines expressed extremely high levels of this oncopro-
tein, ranging from 25 to 52 erbB-2 units/m g protein
(15- to 31-fold the level detected in primary normal
human bronchial epithelial cells; Fig 1). A 24-hour
exposure to either 20 or 80 nmol/L 17-AAGA resulted
in a significant dose-dependent reduction of p185 lev-
els in all NSCLC lines, regardless of their intrinsic lev-
els of p185 expression (Fig 1). These results were con-
sistent with previously published data concerning
depletion of p185 in NSCLC cells after exposure to 17-
AAGA.3,6 In parallel with the inhibition of p185
expression, continuous exposure to 17-AAGA for 96
hours resulted in a dose-dependent inhibition of
NSCLC cell proliferation, with estimated IC50 values
ranging from 60 to 180 nmol/L (Fig 2).
Sequence-dependent enhancement of paclitaxel
cytotoxicity by 17-allylamino 17-demethoxygel-
danamycin. The treatment schedules were designed to
determine whether downward regulation of p185
expression by 17-AAGA would enhance sensitivity of
NSCLC cells to paclitaxel. In schedule A the 17-
AAGA–mediated depletion of p185 occurred concur-
rently with paclitaxel’s effects on microtubules.
Representative dose-response curves of H661 (high
p185) and H1299 (low 185) cells treated with paclitax-
el alone or with the paclitaxel and 17-AAGA combina-
tion (schedule A) are shown in Fig 3, A. The added sup-
pression of cell growth by the drug combination in
H661 cells (20%-30%) compared with cells treated with
paclitaxel alone was higher than the growth inhibitory
effect of 17-AAGA (10%-15% growth inhibition at 20
and 40 nmol/L, respectively). The combination effect
was clearly synergistic. There was a significant dose-
dependent 17-AAGA–mediated reduction of paclitaxel
IC50 values in H661 cells treated with the drug combi-
nation, indicating enhanced sensitivity to paclitaxel’s
cytotoxic effects: 100 ± 11 nmol/L and 71 ± 8 nmol/L
in cells treated with the drug combination at 20 nmol/L
and 40 nmol/L 17-AAGA versus 400 ± 23 nmol/L in
cells treated with paclitaxel alone (P = .0011 and P =
.0006 by the Student t test, respectively). On the other
hand, combination drug exposure had only an additive
cytotoxic effect in H1299 cells; further reduction of the
fractions of survival in the combination-treated cells
was entirely attributable to the antiproliferative effect of
17-AAGA (5% to 15% growth inhibition at 20 nmol/L
and 40 nmol/L 17-AAGA, respectively).
Fig 3, B, depicts the effects of combination drug
treatment on paclitaxel sensitivity in the panel of
NSCLC cell lines. Enhancement of paclitaxel cytotox-
icity by 17-AAGA was observed only in cells that
expressed high levels of p185. The magnitude of sensi-
tization (expressed as the multiplicity of reduction in
paclitaxel IC50 values) in each cell line is depicted in
the graph located in the upper right corner of Fig 3, B.
Impressed with the ability of 17-AAGA to enhance
paclitaxel sensitivity with schedule A, we next examined
Fig 1. Constitutive expression of p185 oncoprotein and its
depletion by 17-AAGA in NSCLC cells. Normal human
bronchial epithelial cells (NHBE) as well as H460 and H1299
cells express low levels of p185. Other cell lines overexpress
this oncoprotein (15- to 31-fold higher than level detected in
normal human bronchial epithelial cells). Exposure to either
20 nmol/L or 80 nmol/L 17-AAGA for 24 hours resulted in
dose-dependent reduction of p185 in all cell lines tested. Data
are mean ± SD for 3 independent experiments.
Fig 2. Dose-dependent growth inhibition of NSCLC in vitro
by 17-AAGA. Cells were seeded in 96-well flat-bottom
microtiter plates and, after overnight incubation, continuously
exposed to varying doses of 17-AAGA for 96 hours. Viable
cells were quantitated by MTT assay. IC50 values, estimated
from dose-response curves, are indicated in parentheses.
Data are mean ± SD for 3 independent experiments.
Fig 3. A, Representative dose-response curves of H661 (high p185) and H1299 (low p185) cells treated with
paclitaxel (Taxol) alone or concurrently with either 20 nmol/L or 40 nmol/L 17-AAGA (schedule A combination).
Data are mean ± SD for 4 independent experiments. B, Reduction of paclitaxel (Taxol) IC50 values by 17-AAGA
in NSCLC cells expressing high levels of p185 (P = .001, P < .0001, P < .0001, P < .0001 for H358, H322, H661,
and H522 cells, respectively, by 1-way analysis of variance). Data are mean ± SD for 4 independent experiments.
Right upper corner graph indicates multiplicity of reduction of paclitaxel IC50 values (indicating enhanced pacli-
taxel sensitivity) in cells treated with paclitaxel and either 20 nmol/L or 40 nmol/L 17-AAGA.
A
B
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Fig 4. A, Representative dose-response curves of H661 (high p185) and H1299 (low p185) cells treated with
paclitaxel (Taxol, Tx) or schedule B drug combination. Exposure of cells to 17-AAGA for 24 hours before pacli-
taxel and 17-AAGA treatment induced paclitaxel resistance, as indicated by higher fractions of viable cells and
translated into elevation of paclitaxel IC50 values. Data are mean ± SD for 4 independent experiments. B,
Significant elevation of paclitaxel IC50 values (indicating decreased paclitaxel sensitivity) by schedule B drug
combination in 5 cell lines studied (2 low p185 and 3 high p185 cell lines).
A
B
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whether pretreating cells with 17-AAGA before combi-
nation drug exposure (schedule B) would further poten-
tiate the effects of paclitaxel. Preliminary experiments
revealed that treating cells with 17-AAGA for 24 hours
enabled maximum inhibition of p185 expression (data
not shown). Interestingly, instead of sensitizing cells to
paclitaxel, 17-AAGA pretreatment rendered NSCLC
cells more resistant to this combination. Representative
dose-response curves of H661 and H1299 cells treated
with paclitaxel alone or with the schedule B drug com-
bination are depicted in Fig 4, A. Higher fractions of
viable cells after treatment with this drug combination
were translated into high paclitaxel IC50 values and thus
paclitaxel resistance. The drastic increase in paclitaxel
IC50 values observed with this drug combination (sum-
marized in Fig 4, B) was noted in all cell lines irrespec-
tive of their levels of p185 expression.
Cancer cells exhibit marked sensitivity to paclitaxel
during G2-M phase yet are quite resistant to microtubule
damage during G1 phase.17,18 Flow cytometric analysis
revealed that 17-AAGA induced a G1-phase arrest in
NSCLC cells, noted within 24 to 48 hours of exposure
(Fig 5); the profound G1-phase arrest induced by 17-
AAGA may have rendered these cells refractory to the
cytotoxic effects of subsequent paclitaxel treatment.
Enhanced induction of apoptosis by the paclitaxel
and 17-allylamino 17-demethoxygeldanamycin com-
bination. Propidium iodide staining and TUNEL assay
analyses of cell cycle kinetics and apoptosis were per-
formed to investigate the mechanism of the synergistic
cytotoxic effect of the paclitaxel and 17-AAGA (sched-
ule A) drug combination in NSCLC cells. H322 cells
treated with schedule A exhibited a G2-M–phase arrest
within 18 hours of drug exposure; this cell cycle arrest
peaked at 48 hours, coinciding with the onset of apop-
tosis. Cells exposed only to paclitaxel followed a simi-
lar time course of G2-M–phase arrest and induction of
apoptosis, albeit at a much lower magnitude (data not
shown). On the other hand, 17-AAGA primarily
induced G1-phase arrest (Fig 5). Paclitaxel and 17-
AAGA combination therapy induced extensive apopto-
sis in H322 and H661 NSCLC cells (Fig 6), exceeding
that observed in cells treated with paclitaxel alone. For
instance, in H322 cells, 57% ± 15% and 69% ± 12%,
respectively, of apoptotic cells were detected after
treatment with paclitaxel and 17-AAGA at 50 and 500
nmol/L, as compared with 14% ± 4% and 24% ± 5% of
apoptotic cells after exposure to paclitaxel (P = .0001,
P = .0008). No apoptosis was observed after 17-AAGA
treatment alone.
Discussion
Appreciation of the molecular basis of chemoresis-
tance may enable the development of pharmacologic
regimens that are selective and efficacious against
high-risk cancers. In recent years the erbB-2 oncogene
has attracted considerable attention as a potential target
for anticancer therapy. Overexpression of the erbB-2
gene has been detected in a wide variety of tumors, cor-
relating with increased basal secretion of vascular
Fig 5. Time-course of induction of cell cycle arrest at G1
phase by 17-AAGA treatment in H1299, H661, and H358 (P
= .42 and P < .0001 [asterisk], P = .01 and P = .03 [number
sign], and P = .19 and P = .0001 [double asterisk] for 17-
AAGA treatment versus control at 24 hours and 48 hours,
respectively, by the Student t test). Data are mean ± SD for 3
independent experiments.
Fig 6. Significant induction of apoptosis in H322 and H661
cells treated for 60 hours with schedule A combination (pacli-
taxel [Taxol] at 50 nmol/L and 500 nmol/L and 17-AAGA at
40 nmol/L). Control preparations were cells treated either
with 17-AAGA or with paclitaxel (P = .0001 [asterisk], P =
.0008 [number sign], P = .001 [double asterisk], and P=
.0001 [double number sign] for schedule A combination ver-
sus paclitaxel alone by Student t test. Data are mean ± SD for
3 independent experiments.
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endothelial growth factor19 and matrix metallopro-
teinases with increased propensity for systemic metas-
tases20 as well as with chemoresistance2-6 in these neo-
plasms. Inhibition of p185 protein expression or
function (by anti-p185 monoclonal antibodies that tar-
get the extracellular moiety of the molecule21 or by
gene therapy techniques that use antisense oligonu-
cleotides or gene sequences encoding an intracellular
anti-p185 single-chain antibody22) induces growth
arrest in cancer cells. Such strategies may have limited
clinical utility because of technical issues pertaining to
the delivery of therapeutic macromolecules to tumor
cells. Therefore the identification of low–molecular-
weight molecules such as 17-AAGA that deplete p185
molecule protein levels at nanomolar concentrations is
of particular interest and practical application.
The mechanisms of antitumor activity mediated by
geldanamycin and 17-AAGA have been well character-
ized.11-14 At low concentrations geldanamycin and 17-
AAGA interact with HSP90 and its homologs to disrupt
their chaperone functions. A myriad intracellular mole-
cules that normally associate with HSP90 are affected
by these compounds, namely Raf-1, mutant p53, cyclin-
dependent kinase 4, and p185. In addition to p185
depletion, geldanamycin and 17-AAGA deplete Raf-1,
shorten the half-life of oncogenic p53 mutants, and
destabilize newly synthesized cyclin-dependent kinase
4. The effects of geldanamycin and 17-AAGA on the
expression of these growth-promoting proteins con-
tribute to the antiproliferative properties of these
drugs.11 Hence it is possible that 17-AAGA enhances
paclitaxel sensitivity in NSCLC cells by mechanisms
other than p185 depletion. No changes in Raf-1 levels
have been observed in NSCLC cells after 48 hours of
exposure to 17-AAGA at the concentrations employed
in this study (data not shown). Moreover, inhibition of
p185 function by the anti-p185 humanized monoclonal
antibody Herceptin (Genentech, Inc, South San
Francisco, Calif) similarly sensitized H358 cell to pacli-
taxel (unpublished data). Moreover, there was a positive
linear correlation between the magnitude of 17-
AAGA–mediated reduction of the p185 oncoprotein
and the multiplicity of reduction in paclitaxel IC50 (the
magnitude of chemosensitization) in NSCLC cells that
positively responded to the combination treatment (data
not shown). These observations, in conjunction with
other published reports,21,23 confirm that enhancement
of paclitaxel’s toxic effects in cells that overexpress
p185 is mediated at least in part by inhibition of p185
expression.
The multidrug resistance (mdr) gene is known to con-
fer chemoresistance in cancer cells; however, paclitaxel
resistance in cells exhibiting p185 overexpression does
not seem to involve the mdr pathway.5,24 Typically, mdr-
1 messenger RNA levels are low or undetectable in
most NSCLCs, except those rare tumors that exhibit
features of neuroendocrine differentiation.24 Expression
of mdr is not induced in cells engineered to express high
levels of p185.6 Recent experiments by Yu and associ-
ates25 have demonstrated that p185 overexpression
induces upregulation of p21/cip1 expression, which in-
hibits activation of p34/cdc2 required for paclitaxel-
induced apoptosis. These observations provide the mol-
ecular basis for use of p185 antagonists in the
management of lung and other solid tumors that fre-
quently exhibit paclitaxel resistance.
In vivo toxicity profiles of geldanamycin and 17-
AAGA have been documented in small-animal models;
renal and hepatic toxicities were dose-limiting
events.26,27 However, the nanomolar concentrations
required to mediate paclitaxel sensitization observed in
our studies are well below the maximal tolerable doses
reported in animal toxicity studies.26,27 Collectively
these data support the evaluation of the combination of
paclitaxel and 17-AAGA in the treatment of patients
with NSCLCs exhibiting p185 overexpression.
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Discussion
Dr Mark K. Ferguson (Chicago, Ill). Is 17-AAGA some-
thing that potentially can be used clinically?
Dr Nguyen. Yes. The National Cancer Institute is setting up
a phase I clinical trial with this compound for solid tumors.
Three other cancer centers, Memorial Sloan-Kettering Cancer
Center included, would participate in this clinical trial.
Dr Ferguson. Is there some time frame for advance admin-
istration of the 17-AAGA that would not induce cell-cycle
reversion to G1 phase?
Dr Nguyen. We have not looked into that. The compound
17-AAGA has been shown to deplete p185 protein maximal-
ly after 8 hours of exposure. Pretreatment of cells for 8 hours
before paclitaxel thus might have a beneficial effect, but we
have not looked into that yet.
Dr Valerie W. Rusch (New York, NY). Is this a p53-inde-
pendent event?
Dr Nguyen.Yes. The G1 arrest has been shown to be occur-
ring in cells that have mutated or delete p53. For example,
H1299 and H358 are p53-null. The G1 arrest is a p53-inde-
pendent phenomenon.
Dr Rusch. Was the normal human bronchial epithelial cell
line that you used the BEA52B cell line or a different cell line?
Dr Nguyen. The normal human bronchial epithelial cells
were human cells that we purchased from Clonetics. These
primary cells grow for about 4 to 6 passages and terminally
differentiate.
Dr Rusch. So they were from your own short-term cultures
that you set up yourself?
Dr Nguyen. The normal human bronchial epithelial cells
are primary cells, not a line cell, and maintained in short-term
culture according to the manufacturer’s instruction.
Dr Rusch. Was there any direct cytotoxic effect on the
human cells with this agent?
Dr Nguyen. We observed that when we grew the normal
human cells to confluence in culture for 96 hours and treated
that culture with the drug combination there was no enhanced
toxic effect of paclitaxel with this combination. So the drug
combination seems to be selective for proliferating malignant
cells.
